Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Cardiovascular Disease Prevention Policy in Human Immunodeficiency Virus: Recommendations From a Modeling Study.

Smit M, van Zoest RA, Nichols BE, Vaartjes I, Smit C, van der Valk M, van Sighem A, Wit FW, Hallett TB, Reiss P; Netherlands AIDS Therapy Evaluation in The Netherlands (ATHENA) Observational HIV Cohort.

Clin Infect Dis. 2018 Feb 10;66(5):743-750. doi: 10.1093/cid/cix858.

2.

Tuberculosis.

Bloom BR, Atun R, Cohen T, Dye C, Fraser H, Gomez GB, Knight G, Murray M, Nardell E, Rubin E, Salomon J, Vassall A, Volchenkov G, White R, Wilson D, Yadav P.

In: Holmes KK, Bertozzi S, Bloom BR, Jha P, editors. Major Infectious Diseases. 3rd edition. Washington (DC): The International Bank for Reconstruction and Development / The World Bank; 2017 Nov 3. Chapter 11.

3.

Impact of clinical and therapeutic factors on incident cardiovascular and cerebrovascular events in a population-based cohort of HIV-infected and non-HIV-infected adults.

Tripathi A, Liese AD, Winniford MD, Jerrell JM, Albrecht H, Rizvi AA, Zhang J, Duffus WA.

Clin Cardiol. 2014 Sep;37(9):517-22. doi: 10.1002/clc.22311.

4.

Projecting 10-year, 20-year, and Lifetime Risks of Cardiovascular Disease in Persons Living With Human Immunodeficiency Virus in the United States.

Losina E, Hyle EP, Borre ED, Linas BP, Sax PE, Weinstein MC, Rusu C, Ciaranello AL, Walensky RP, Freedberg KA.

Clin Infect Dis. 2017 Oct 15;65(8):1266-1271. doi: 10.1093/cid/cix547.

5.

Mobile phone-based interventions for improving adherence to medication prescribed for the primary prevention of cardiovascular disease in adults.

Palmer MJ, Barnard S, Perel P, Free C.

Cochrane Database Syst Rev. 2018 Jun 22;6:CD012675. doi: 10.1002/14651858.CD012675.pub2. Review.

7.

HIV infection and cardiovascular disease.

Hemkens LG, Bucher HC.

Eur Heart J. 2014 Jun 1;35(21):1373-81. doi: 10.1093/eurheartj/eht528. Epub 2014 Jan 9. Review.

PMID:
24408888
8.

Behavioral and Pharmacotherapy Weight Loss Interventions to Prevent Obesity-Related Morbidity and Mortality in Adults: An Updated Systematic Review for the U.S. Preventive Services Task Force [Internet].

LeBlanc EL, Patnode CD, Webber EM, Redmond N, Rushkin M, O’Connor EA.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 Sep.

9.

Multiple risk factor interventions for primary prevention of cardiovascular disease in low- and middle-income countries.

Uthman OA, Hartley L, Rees K, Taylor F, Ebrahim S, Clarke A.

Cochrane Database Syst Rev. 2015 Aug 4;(8):CD011163. doi: 10.1002/14651858.CD011163.pub2. Review.

10.

Cardiovascular disease incidence projections in the TREAT Asia HIV Observational Database (TAHOD).

Bijker R, Kumarasamy N, Kiertiburanakul S, Pujari S, Lam W, Chaiwarith R, Wong WW, Kamarulzaman A, Kantipong P, Avihingsanon A, Nguyen KV, Tanuma J, Ng OT, Sim BL, Merati TP, Choi JY, Ditangco R, Yunihastuti E, Sun LP, Do CD, Ross J, Law M; TREAT Asia HIV Observational Database (TAHOD) of IeDEA Asia-Pacific.

Antivir Ther. 2019 Mar 5. doi: 10.3851/IMP3298. [Epub ahead of print]

PMID:
30833516
11.

Aspirin Use in Adults: Cancer, All-Cause Mortality, and Harms: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Whitlock EP, Williams SB, Burda BU, Feightner A, Beil T.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2015 Sep.

12.

Cardiovascular disease risk among Chinese antiretroviral-naïve adults with advanced HIV disease.

Guo F, Hsieh E, Lv W, Han Y, Xie J, Li Y, Song X, Li T.

BMC Infect Dis. 2017 Apr 20;17(1):287. doi: 10.1186/s12879-017-2358-0.

13.
14.

START or SMART? Timing of Antiretroviral Therapy Initiation and Cardiovascular Risk for People With Human Immunodeficiency Virus Infection.

Siedner MJ.

Open Forum Infect Dis. 2016 Feb 9;3(1):ofw032. doi: 10.1093/ofid/ofw032. eCollection 2016 Jan. Review.

15.

Association of clinical and therapeutic factors with incident dyslipidemia in a cohort of human immunodeficiency virus-infected and non-infected adults: 1994-2011.

Tripathi A, Jerrell JM, Liese AD, Zhang J, Rizvi AA, Albrecht H, Duffus WA.

Metab Syndr Relat Disord. 2013 Dec;11(6):417-26. doi: 10.1089/met.2013.0017. Epub 2013 Aug 2.

PMID:
23909647
16.

Estimating the future burden of cardiovascular disease and the value of lipid and blood pressure control therapies in China.

Stevens W, Peneva D, Li JZ, Liu LZ, Liu G, Gao R, Lakdawalla DN.

BMC Health Serv Res. 2016 May 10;16:175. doi: 10.1186/s12913-016-1420-8.

17.

HIV infection, aging and cardiovascular disease: epidemiology and prevention.

Petoumenos K, Worm SW.

Sex Health. 2011 Dec;8(4):465-73. doi: 10.1071/SH11020. Review.

PMID:
22127031
18.

Hypertension Among HIV-infected Patients in Clinical Care, 1996-2013.

Okeke NL, Davy T, Eron JJ, Napravnik S.

Clin Infect Dis. 2016 Jul 15;63(2):242-8. doi: 10.1093/cid/ciw223. Epub 2016 Apr 18.

20.

The Economic Impact of Smoking and of Reducing Smoking Prevalence: Review of Evidence.

Ekpu VU, Brown AK.

Tob Use Insights. 2015 Jul 14;8:1-35. doi: 10.4137/TUI.S15628. eCollection 2015. Review.

Supplemental Content

Support Center